StemCell Therapy

As the world charges to vaccinate the population against the coronavirus, gene therapy developers are locked in a counterintuitive race. Instead of training the immune system to recognize and combat a virus, theyre trying to do the opposite: designing viruses the body has never seen, and cant fight back against.

Its OK, really: These are adeno-associated viruses, which are common and rarely cause symptoms. That makes them the perfect vehicle for gene therapies, which aim to treat hereditary conditions caused by a single faulty gene. But they introduce a unique challenge: Because these viruses already circulate widely, patients immune systems may recognize the engineered vectors and clobber them into submission before they can do their job.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

See the original post here:
Scientists use machine learning to tackle a big challenge in gene therapy - STAT

This entry was posted on February 14, 2021 at 7:17 pm and is filed under Gene therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |